- Home
- UNB vs CRGX Comparison
UNB vs CRGX Comparison
Compare UNB & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNB
- CRGX
- Stock Information
- Founded
- UNB 1891
- CRGX 2021
- Country
- UNB United States
- CRGX United States
- Employees
- UNB N/A
- CRGX N/A
- Industry
- UNB Major Banks
- CRGX
- Sector
- UNB Finance
- CRGX
- Exchange
- UNB Nasdaq
- CRGX Nasdaq
- Market Cap
- UNB 159.0M
- CRGX 190.0M
- IPO Year
- UNB 1998
- CRGX 2023
- Fundamental
- Price
- UNB $29.49
- CRGX $4.25
- Analyst Decision
- UNB
- CRGX Hold
- Analyst Count
- UNB 0
- CRGX 7
- Target Price
- UNB N/A
- CRGX $4.67
- AVG Volume (30 Days)
- UNB 11.8K
- CRGX 569.8K
- Earning Date
- UNB 07-16-2025
- CRGX 05-08-2025
- Dividend Yield
- UNB 4.88%
- CRGX N/A
- EPS Growth
- UNB N/A
- CRGX N/A
- EPS
- UNB 1.94
- CRGX N/A
- Revenue
- UNB $47,827,000.00
- CRGX N/A
- Revenue This Year
- UNB N/A
- CRGX $58.18
- Revenue Next Year
- UNB N/A
- CRGX N/A
- P/E Ratio
- UNB $15.20
- CRGX N/A
- Revenue Growth
- UNB N/A
- CRGX N/A
- 52 Week Low
- UNB $21.00
- CRGX $3.00
- 52 Week High
- UNB $37.70
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- UNB 37.26
- CRGX 53.57
- Support Level
- UNB $27.73
- CRGX $3.78
- Resistance Level
- UNB $34.59
- CRGX $4.27
- Average True Range (ATR)
- UNB 1.77
- CRGX 0.18
- MACD
- UNB -0.60
- CRGX 0.03
- Stochastic Oscillator
- UNB 21.28
- CRGX 88.79
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.